Corvus Pharmaceuticals Inc. (CRVS), a clinical-stage biopharmaceutical company, is scheduled to announce interim data from its Phase 1 trial of Soquelitinib in moderate to severe atopic dermatitis today, December 18, 2024.
Soquelitinib (formerly known as CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase). ITK is an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function.
The phase I trial of Soquelitinib is designed to enroll 64 patients who have failed at least one prior therapy. Four different 28-day dosing regimens of Soquelitinib are evaluated against a placebo group in the study. The endpoints include safety and improvement in the Eczema Area and Severity Index.
Corvus will host a conference call and webcast today December 18, 2024, at 8:00 a.m. ET / 5:00 a.m. PT to discuss the atopic dermatitis trial data.
CRVS closed Tuesday's (Dec.17.2024) trading at $7.39, up 7.10%. In after-hours trading, the stock was up nearly 22% at $9.00.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.